Dianthus Therapeutics, Inc.
NASDAQTotal Valuation
Dianthus Therapeutics, Inc. carries a market capitalization of 5.07B, placing it among publicly traded companies globally. Its enterprise value stands at 4.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.07B |
| Enterprise Value | 4.46B |
Share Statistics
Dianthus Therapeutics, Inc. currently has 54.80M shares outstanding.
| Shares Outstanding | 54.80M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2,391.27, and the price-to-book ratio stands at 4.56.
| PE Ratio | N/A |
| PS Ratio | 2,391.27 |
| PB Ratio | 4.56 |
| P/TBV Ratio | 4.56 |
| P/FCF Ratio | -29.30 |
| P/OCF Ratio | -29.30 |
Enterprise Valuation
| EV / Sales | 2,340.45 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Dianthus Therapeutics, Inc. maintains a current ratio of 26.10, meaning it holds 26.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 26.10 |
| Quick Ratio | 25.79 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -26.07 |
| Return on Assets (ROA) | -24.98 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Dianthus Therapeutics, Inc.'s stock has gained approximately 153.0971% over the past 52 weeks. The 50-day moving average sits at 106.44, while the 200-day moving average is 79.79.
| Beta (5Y) | N/A |
| 52-Week Price Change | 153.0971% |
| 50-Day Moving Average | 106.44 |
| 200-Day Moving Average | 79.79 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Dianthus Therapeutics, Inc. generated 1.90M in revenue and converted that into -192.25M in net income, yielding earnings per share of -4.12. EBITDA reached -217.46M, while operating income came in at -217.84M.
| Revenue | 1.90M |
| Gross Profit | N/A |
| Operating Income | -217.84M |
| Pretax Income | -192.25M |
| Net Income | -192.25M |
| EBITDA | -217.46M |
| EBIT | -217.84M |
| Earnings Per Share (EPS) | -4.12 |
Balance Sheet
Dianthus Therapeutics, Inc. holds 886.81M in cash and equivalents against 1.29M in total debt, resulting in a net debt position of -110.55M. Total book value stands at 1.17B, with working capital of 863.15M providing operational flexibility.
| Cash & Cash Equivalents | 886.81M |
| Total Debt | 1.29M |
| Net Debt | -110.55M |
| Equity (Book Value) | 1.17B |
| Book Value Per Share | 21.39 |
| Working Capital | 863.15M |
Cash Flow
Dianthus Therapeutics, Inc. produced -155.37M in operating cash flow over the past twelve months.
| Operating Cash Flow | -155.37M |
| Capital Expenditures | N/A |
| Free Cash Flow | -155.37M |
| FCF Per Share | -3.33 |
Margins
Dianthus Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -11,441.39 and net profit margin of -10,096.95 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -11,441.39 |
| Pretax Margin | -10,096.95 |
| Profit Margin | -10,096.95 |
| EBITDA Margin | -11,421.48 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -19.27 |
| FCF Yield | -3.41 |
Stock Splits
Dianthus Therapeutics, Inc.'s most recent stock split took place on September 12, 2023 with a 16:1 split ratio.
| Last Split Date | 9/12/2023 |
| Split Ratio | 16:1 |
Scores
Dianthus Therapeutics, Inc. posts an Altman Z-Score of 77.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 77.47 |